BioCryst (BCRX) | Stock Overview & Key Data
BioCryst Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $37.25 on March 6, 2000
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
BioCryst
BCRX
|
2.20B Mid-cap | 7.47% | 0.44% | -2.58% | 19.37% | 20.80% | -16.10% | 17.41% | -45.25% | 210.71% | 117.50% | -30.40% |
|
Zoetis
ZTS
|
49.75B Large-cap | 0.16% | 3.42% | -31.08% | -32.94% | -36.81% | -51.58% | -53.40% | -57.08% | 71.34% | 156.59% | 156.59% |
|
Haleon Plc - ADR
HLN
|
42.40B Large-cap | 2.02% | 1.23% | -13.29% | -7.73% | -9.30% | -16.01% | 8.43% | 23.21% | 23.21% | 23.21% | 23.21% |
|
Alkermes plc
ALKS
|
5.55B Mid-cap | 4.50% | 18.36% | 58.43% | 57.47% | 56.97% | 48.44% | 37.56% | 81.33% | 7.03% | 166.59% | 137.55% |
|
Lantheus Holdings
LNTH
|
5.39B Mid-cap | 4.66% | 11.46% | 33.34% | 57.23% | 55.60% | 34.29% | 18.41% | 324.53% | 3,800.00% | 1,525.51% | 1,525.51% |
|
Amneal
AMRX
|
4.15B Mid-cap | 18.45% | 36.13% | 36.01% | 30.34% | 28.28% | 109.03% | 497.79% | 211.54% | 10.20% | 10.20% | 10.20% |
Ownership & Short Interest
Calculate Your BioCryst Investment Returns
Long-Term Investment Performance Analysis
BioCryst stock price in Jul 2016 was $3.08, A $1,000.00 lump sum investment in BioCryst made 9 years ago would be worth approximately $2,941.56 today, representing a strong return of 194.16%. This translates to an annualized return (CAGR) of 11.50%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BCRX's 52-week high and low?
- In the last 52 weeks, BioCryst reached a high of $10.47 (on June 16, 2025) and a low of $6.00 (on October 14, 2025).
- What is the market cap and P/E ratio for BCRX?
- Curious about BioCryst's size and valuation? Its market capitalization stands at 2.20B. When it comes to valuation, the P/E ratio (trailing twelve months) is 7.09, and the forward P/E (looking ahead) is 10.70.
- Does BCRX pay dividends? If so, what's the yield?
- As for dividends, BioCryst isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are BioCryst's main competitors or similar companies to consider before investing?
When looking at BioCryst, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS49.75B Healthcare Drug Manufacturers - Specialty & Generic -51.58% -53.40% Haleon Plc - ADR
HLN42.40B Healthcare Drug Manufacturers - Specialty & Generic -16.01% 8.43% Alkermes plc
ALKS5.55B Healthcare Drug Manufacturers - Specialty & Generic 48.44% 37.56% Lantheus Holdings
LNTH5.39B Healthcare Drug Manufacturers - Specialty & Generic 34.29% 18.41% Amneal
AMRX4.15B Healthcare Drug Manufacturers - Specialty & Generic 109.03% 497.79% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for BioCryst Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of BioCryst's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -221.45%, the Debt to Equity ratio from the most recent quarter is -4.01, and its Gross Profit Margin stands at 97.66%.
- What is the recent revenue and earnings growth for BCRX?
- Looking at BioCryst's growth, its revenue over the trailing twelve months (TTM) was $875M. Compared to the same quarter last year (YoY), quarterly revenue grew by 209.10%, and quarterly earnings saw a YoY growth of 209.09%.
- How much of BCRX stock is held by insiders and institutions?
- Wondering who owns BioCryst stock? Company insiders (like executives and directors) hold about 1.31% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 89.14%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.